Dr. Daniel F. Soteres, MD
Allergy & Immunology (Allergy Physician)
2709 N Tejon Street
Colorado Springs, CO 80907
Who else practices at this address →
El Paso County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 160
Licensed in Colorado since 2005, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: Tulane University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy Physician primary
CO license 43625 (first issued 2005; transferred to compact physician) · LA license 024632
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Asthma and Allergy Associates, PC (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 160
- Services billed
- 7,400
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 2,860 | 45 |
| Professional service for preparation and provision of 1 or more antigens | 664 | 31 |
| Professional service for multiple injections of allergen | 569 | 26 |
| Test for allergy using allergenic extract injected into skin | 445 | 37 |
| Established patient office or other outpatient visit, 30-39 minutes | 104 | 75 |
| Test to measure rate of airflow | 100 | 75 |
| New patient office or other outpatient visit, 45-59 minutes | 50 | 50 |
| Established patient office or other outpatient visit, 20-29 minutes | 42 | 34 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Colorado Springs, CO | 78 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Colorado Springs, CO | 50 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Colorado Springs, CO | 48 |
| Azelastine Hcl Other prescribers in Colorado Springs, CO | 42 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Colorado Springs, CO | 40 |
| Fluticasone Propionate Other prescribers in Colorado Springs, CO | 40 |
| Takhzyro (lanadelumab-flyo) | 38 |
| Privigen (immun glob g(igg)/pro/iga 0-50) | 22 |
| Xolair (omalizumab) | 21 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Colorado Springs, CO | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 260 payments worth $115,774 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $33,073 |
|---|---|
| Pharming Healthcare, Inc. | $14,442 |
| Biocryst US Sales Co., LLC | $13,384 |
| Ionis Pharmaceuticals, Inc. | $13,092 |
| AstraZeneca Pharmaceuticals LP | $12,638 |
| Csl Behring | $11,448 |
| Biocryst Pharmaceuticals, Inc. | $10,857 |
| Genzyme Corporation | $4,119 |
| Compensation for services other than consulting (speaking, faculty) | $57,235 |
|---|---|
| Consulting Fee | $44,526 |
| Travel and Lodging | $7,837 |
| Food and Beverage | $6,176 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $10,010 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,793 |
| Biocryst US Sales Co., LLC Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) ORLADEYO · Immunology | $6,555 |
| Biocryst Pharmaceuticals, Inc. Jan 8, 2025 | Consulting Fee | $6,501 |
| Csl Behring Oct 8, 2025 | Consulting Fee Andembry · Hematology | $5,301 |
| Biocryst US Sales Co., LLC Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) ORLADEYO · Immunology | $4,830 |
| Pharming Healthcare, Inc. Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) RUCONEST · BIOLOGIC | $4,613 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 26, 2025 | Consulting Fee TAKHZYRO · GENETIC DISEASE | $4,290 |
| Ionis Pharmaceuticals, Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) DAWNZERA · PULMONOLOGY & IMMUNOLOGY | $4,170 |
| Ionis Pharmaceuticals, Inc. Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) DAWNZERA · PULMONOLOGY & IMMUNOLOGY | $4,170 |
All 66 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Biocryst Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee ORLADEYO · Immunology | $3,850 |
| Takeda Pharmaceuticals U.S.A., Inc. Dec 9, 2025 | Travel and Lodging TAKHZYRO · GENETIC DISEASE · travel to SEATTLE, WA · in-kind | $324 |
| Takeda Pharmaceuticals U.S.A., Inc. Dec 8, 2025 | Consulting Fee | $3,575 |
| Takeda Pharmaceuticals U.S.A., Inc. Dec 3, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. Dec 3, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $34.69 |
| Takeda Pharmaceuticals U.S.A., Inc. Dec 3, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $26.40 |
| Takeda Pharmaceuticals U.S.A., Inc. Dec 3, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $10.78 |
| Takeda Pharmaceuticals U.S.A., Inc. Dec 1, 2025 | Compensation for services other than consulting (speaking, faculty) TAKHZYRO · GENETIC DISEASE | $1,788 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $10,010 |
| Csl Behring Nov 20, 2025 | Consulting Fee Andembry · Hematology | $2,062 |
| Pharming Healthcare, Inc. Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) RUCONEST · BIOLOGIC | $4,613 |
| Pharming Healthcare, Inc. Nov 19, 2025 | Travel and Lodging RUCONEST · BIOLOGIC · travel to DENVER, CO · in-kind | $89.60 |
| Biocryst US Sales Co., LLC Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) ORLADEYO · Immunology | $6,555 |
| Biocryst US Sales Co., LLC Nov 18, 2025 | Travel and Lodging ORLADEYO · Immunology · travel to Los Angeles, CA | $294 |
| Biocryst US Sales Co., LLC Nov 18, 2025 | Travel and Lodging ORLADEYO · Immunology · travel to Los Angeles, CA · in-kind | $279 |
| Biocryst US Sales Co., LLC Nov 18, 2025 | Travel and Lodging ORLADEYO · Immunology · travel to Los Angeles, CA · in-kind | $224 |
| Ionis Pharmaceuticals, Inc. Nov 7, 2025 | Consulting Fee DAWNZERA · PULMONOLOGY & IMMUNOLOGY | $3,475 |
| Biocryst Pharmaceuticals, Inc. Nov 5, 2025 | Travel and Lodging ORLADEYO · Immunology · travel to Orlando, FL · in-kind | $388 |
| Biocryst Pharmaceuticals, Inc. Nov 5, 2025 | Travel and Lodging ORLADEYO · Immunology · travel to Orlando, FL | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 23, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $552 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 23, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 23, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $132 |
| Csl Behring Oct 8, 2025 | Consulting Fee Andembry · Hematology | $5,301 |
| Ionis Pharmaceuticals, Inc. Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) DAWNZERA · PULMONOLOGY & IMMUNOLOGY | $4,170 |
| Ionis Pharmaceuticals, Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) DAWNZERA · PULMONOLOGY & IMMUNOLOGY | $4,170 |
| Novartis Pharmaceuticals Corporation Sep 26, 2025 | Travel and Lodging Rhapsido · Immunology · travel to Chicago, IL · in-kind | $397 |
| Novartis Pharmaceuticals Corporation Sep 26, 2025 | Travel and Lodging Rhapsido · Immunology · travel to Chicago, IL · in-kind | $319 |
| AstraZeneca Pharmaceuticals LP Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $950 |
| AstraZeneca Pharmaceuticals LP Sep 25, 2025 | Consulting Fee AIRSUPRA · Respiratory Company’s descriptionResearch Related Service | $698 |
| Ionis Pharmaceuticals, Inc. Sep 20, 2025 | Travel and Lodging DAWNZERA · PULMONOLOGY & IMMUNOLOGY · travel to CARLSBAD, CA · in-kind | $272 |
| Ionis Pharmaceuticals, Inc. Sep 19, 2025 | Travel and Lodging DAWNZERA · PULMONOLOGY & IMMUNOLOGY · travel to CARLSBAD, CA · in-kind | $272 |
| Ionis Pharmaceuticals, Inc. Sep 19, 2025 | Travel and Lodging DAWNZERA · PULMONOLOGY & IMMUNOLOGY · travel to CARLSBAD, CA · in-kind | $242 |
| Ionis Pharmaceuticals, Inc. Sep 19, 2025 | Travel and Lodging DAWNZERA · PULMONOLOGY & IMMUNOLOGY · travel to CARLSBAD, CA · in-kind | $118 |
| AstraZeneca Pharmaceuticals LP Sep 10, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $950 |
| Csl Behring Aug 8, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology | $884 |
| Biocryst US Sales Co., LLC Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) ORLADEYO · Immunology | $4,830 |
| Csl Behring Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology | $750 |
| Csl Behring Jul 10, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology | $736 |
| Pharming Healthcare, Inc. Jul 9, 2025 | Consulting Fee RUCONEST · BIOLOGIC | $3,075 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 26, 2025 | Consulting Fee TAKHZYRO · GENETIC DISEASE | $4,290 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 26, 2025 | Travel and Lodging TAKHZYRO · GENETIC DISEASE · travel to PALM BEACH, FL · in-kind | $1,096 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 26, 2025 | Travel and Lodging TAKHZYRO · GENETIC DISEASE · travel to PALM BEACH, FL · in-kind | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 26, 2025 | Travel and Lodging TAKHZYRO · GENETIC DISEASE · travel to PALM BEACH, FL · in-kind | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 26, 2025 | Travel and Lodging TAKHZYRO · GENETIC DISEASE · travel to PALM BEACH, FL · in-kind | $44.00 |
| Csl Behring Jun 25, 2025 | Consulting Fee Andembry · Hematology | $1,178 |
| AstraZeneca Pharmaceuticals LP May 21, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $450 |
| Genzyme Corporation May 20, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $1,266 |
| Pharming Healthcare, Inc. Apr 1, 2025 | Consulting Fee RUCONEST · BIOLOGIC | $3,075 |
| Biocryst US Sales Co., LLC Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) ORLADEYO · Immunology | $690 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 20, 2025 | Consulting Fee TAKHZYRO · GENETIC DISEASE | $1,582 |
| Pharming Healthcare, Inc. Mar 18, 2025 | Consulting Fee RUCONEST · BIOLOGIC | $3,075 |
| Genzyme Corporation Mar 15, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $2,532 |
| AstraZeneca Pharmaceuticals LP Mar 5, 2025 | Consulting Fee | $1,860 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,793 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 21, 2025 | Travel and Lodging travel to LA JOLLA, CA · in-kind | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 21, 2025 | Travel and Lodging travel to LA JOLLA, CA · in-kind | $30.00 |
| AstraZeneca Pharmaceuticals LP Feb 18, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $450 |
| AstraZeneca Pharmaceuticals LP Feb 14, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $930 |
| AstraZeneca Pharmaceuticals LP Feb 13, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $3,700 |
| AstraZeneca Pharmaceuticals LP Feb 6, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $950 |
| AstraZeneca Pharmaceuticals LP Feb 6, 2025 | Travel and Lodging AIRSUPRA · Respiratory · travel to Keystone, CO · in-kind Company’s descriptionSpeaker Expenses | $438 |
| AstraZeneca Pharmaceuticals LP Feb 6, 2025 | Travel and Lodging AIRSUPRA · Respiratory · travel to Keystone, CO · in-kind Company’s descriptionSpeaker Expenses | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. Jan 22, 2025 | Travel and Lodging travel to LA JOLLA, CA · in-kind | $504 |
| Takeda Pharmaceuticals U.S.A., Inc. Jan 22, 2025 | Travel and Lodging travel to LA JOLLA, CA · in-kind | $431 |
| Takeda Pharmaceuticals U.S.A., Inc. Jan 22, 2025 | Travel and Lodging travel to LA JOLLA, CA · in-kind | $232 |
| Biocryst Pharmaceuticals, Inc. Jan 8, 2025 | Consulting Fee | $6,501 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 4 companies. The companies reported $693,815 in research payments for these studies, mostly to the institutions running them.
- A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy
Novartis Pharmaceuticals Corporation - A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Contro…
Novartis Pharmaceuticals Corporation - ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide …
AstraZeneca Pharmaceuticals LP - A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urtic…
Novartis Pharmaceuticals Corporation - Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT04530123 - A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (…
Novartis Pharmaceuticals Corporation - A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy
Novartis Pharmaceuticals Corporation - A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the U…
AstraZeneca Pharmaceuticals LP - Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Eli Lilly and Company · Completed · NCT04392154 - A study of TAK-062 in treatment of active celiac disease in participants attempting a gluten-free diet
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.